TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample. Read More...
Select Product(s)

TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)

OP-101-1003

Price
 
 

TruSight Tumor 170 Kit (24 Samples)

OP-101-1004

Price
 
 

TruSight Tumor 170 Kit, For Use with NextSeq plus Watson for Genomics

20018621

Price
 
 

TruSight Tumor 170 Kit plus Watson for Genomics

20018622

Price
 
 

Product Highlights

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

  • Comprehensive Coverage of Cancer-Related Variants
    Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
  • Accurate Results from Low-Quality Samples1
    Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.

Specifications

Project Recommendations

Instrument Recommended Number of Samples Read Length
NextSeq 550 System Samples per run (high output): 16 (8 DNA + 8 RNA), 10 if DNA only, 16 if RNA only 2 × 101 bp (max recommended)
HiSeq 2500 System Samples per run (rapid run): 12 (6 DNA + 6 RNA), 6 if DNA only, 12 if RNA only 2 × 101 bp (max recommended)
NovaSeq 6000 System Samples per run (dual flow cell): S1: 96, S2: 96, S4: 192 (limited by index combinations) 2 x 100 bp (max recommended)

Product Comparison

TruSight Tumor 170 TruSight Tumor 15 AmpliSeq for Illumina Focus Panel AmpliSeq for Illumina Comprehensive Panel v3 AmpliSeq for Illumina Cancer Hotspot Panel v2
Assay Time ~2 days (Library Prep) 7 hours 5-6 hours (library prep only; doesn't include library quantification, normalization, or pooling time) 5-6 hours (library prep only; doesn't include library quantification, normalization, or pooling time) 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time)
Cancer Type Solid Tumor Solid Tumor Solid Tumor Solid Tumor Pan-Cancer, Solid Tumor
Content Specifications Probes enrich for full coding sequences of 170 genes. Calls single nucleotide variants, small insertions, and deletions in 151 genes, amplifications in 59 genes, and fusions plus splice variants in 55 genes. Amplifies 250 amplicons from 15 genes associated with solid tumors DNA and RNA targets for 52 oncogenes DNA and RNA targets for 161 oncogenes Hotspot regions of 50 genes with known associations to cancer
Description Perform comprehensive somatic variant detection research in solid tumors using variant calling information from both DNA and RNA. Focused panel to study relevant solid tumor somatic variants in 15 genes using a simple workflow. Somatic analysis research on 52 genes associated with solid tumor cancers. Somatic analysis research on hotspot and full-length targets of genes associated with solid tumor cancers. Somatic analysis research into hotspot regions of 50 cancer-related genes.
Hands-On Time ~10.5 hours 3.5 hours < 1.5 hours < 1.5 hours < 1.5 hours
Input Quantity 40 ng DNA and/or RNA 20 ng 1–100 ng (10 ng recommended per pool) 1–100 ng (10 ng recommended per pool) 1–100 ng (10 ng recommended per pool)
Method Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing Amplicon Sequencing , Targeted DNA Sequencing Amplicon Sequencing , Targeted DNA Sequencing , Targeted RNA Sequencing Amplicon Sequencing , Targeted DNA Sequencing , Targeted RNA Sequencing Amplicon Sequencing , Targeted DNA Sequencing
Multiplexing Up to 32-plex for DNA using both index sets, up to 16-plex for RNA 1-24-plex 96 dual index combinations 96 dual index combinations 96 dual index combinations
Nucleic Acid Type RNA, DNA DNA DNA, RNA DNA, RNA DNA
Specialized Sample Types FFPE Tissue, Low-Input Samples FFPE Tissue, Low-Input Samples Blood, FFPE Tissue Blood, FFPE Tissue Blood, FFPE Tissue
Species Category Human Human Human Human Human

Method-Specific Workflow Example

 

Case Studies

Accurate Identification of Cancer Biomarkers Paves the Way for Personalized Medicine

TruSight Tumor 170 Panel enables translational researchers to seek answers to multiple questions in one assay.

Read Interview

Scientific Posters

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More

Related Products

TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.


TruSight RNA Pan-Cancer

Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.


TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.


References
  1. Beta study. Data on file. March 2017.